Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To enhance the oral bioavailability of the antioxidants trans-resveratrol and trans-ε-viniferin from Vineatrol30 grapevine-shoot extract, the native powder was incorporated into micelles. A single dose, single blind, two arms crossover trial was conducted. Plasma and urine samples were collected at intervals up to 24 h after oral intake of native or micellar Vineatrol30 (500 mg), and resveratrol content was quantified and compared between formulations. Tolerability of the dose was also controlled by safety parameters in plasma.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Vineatrol30 native powder | Experimental | 500 mg Vineatrol30 containing 30 mg trans-resveratrol and 75.2 mg trans-epsilon-viniferin |
|
| Vineatrol30 micelles | Experimental | 500 mg Vineatrol30 micelles containing 30 mg trans-resveratrol and 75.2 mg trans-epsilon-viniferin |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Vineatrol 30 native powder | Dietary Supplement |
| ||
| Vineatrol 30 micelles |
| Measure | Description | Time Frame |
|---|---|---|
| Mean area under the curve (AUC) of plasma concentration vs. time of total trans-resveratrol [nmol/L*h] | Total trans-resveratrol after deconjugation with beta-glucuronidase/sulphatase | 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose |
| Mean area under the curve (AUC) of plasma concentration vs. time of total trans-epsilon-viniferin [nmol/L*h] | Total trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase | 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose |
| Mean maximum plasma concentration (Cmax) of total trans-resveratrol [nmol/L] | Total trans-resveratrol after deconjugation with beta-glucuronidase/sulphatase | 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose |
| Mean maximum plasma concentration (Cmax) of total trans-epsilon-viniferin [nmol/L] | Total trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase | 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose |
| Time to reach maximum plasma concentration (Tmax) of total trans-resveratrol [h] | Total trans-resveratrol after deconjugation with beta-glucuronidase/sulphatase | 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose |
| Time to reach maximum plasma concentration (Tmax) of total trans-epsilon-viniferin [h] | Total trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase | 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose |
| Cumulative urinary excretion of total trans-resveratrol [nmol/g creatinine] |
| Measure | Description | Time Frame |
|---|---|---|
| Serum aspartate transaminase activity [U/L] | 0, 4, 24h post-dose | |
| Serum alanine transaminase activity [U/L] | 0, 4, 24h post-dose | |
| Serum gamma-glutamyl transferase activity [U/L] |
Not provided
Inclusion Criteria:
Healthy Volunteers with blood chemistry values within normal ranges
Age: 18-35 years
BMI: 19-25 kg/m2
Exclusion Criteria:
Pregnancy or lactation
Alcohol and/or drug abuse
Use of dietary supplements or any medications, except contraceptives
Any known malignant, metabolic and endocrine diseases
Previous cardiac infarction
Dementia
Participation in a clinical trial within the past 6 weeks prior to recruitment
Smoking
Physical activity of more than 5 h/wk
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jan Frank, Prof. Dr | University of Hohenheim | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Hohenheim | Stuttgart | Baden-Wurttemberg | 70599 | Germany |
Not provided
| Label | URL |
|---|---|
| Website of the research group | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Dietary Supplement |
|
Total trans-resveratrol after deconjugation with beta-glucuronidase/sulphatase |
| 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose |
| Cumulative urinary excretion of total trans-epsilon-viniferin [nmol/g creatinine] | Total trans-epsilon-viniferin after deconjugation with beta-glucuronidase/sulphatase | 0, 0.5, 1, 2, 4, 6, 8 and 24 h post dose |
| 0, 4, 24h post-dose |
| Serum alkaline phosphatase activity [U/L] | 0, 4, 24h post-dose |
| Serum bilirubin | 0, 4, 24h post-dose |
| Serum uric acid [mg/dL] | 0, 4, 24h post-dose |
| Serum creatinine [mg/dL] | 0, 4, 24h post-dose |
| Serum total cholesterol [mg/dL] | 0, 4, 24h post-dose |
| Serum HDL cholesterol [mg/dL] | 0, 4, 24h post-dose |
| Serum LDL cholesterol [mg/dL] | 0, 4, 24h post-dose |
| Serum triacylglycerols [mg/dL] | 0, 4, 24h post-dose |
| LDL/HDL cholesterol ratio | 0, 4, 24h post-dose |
| Serum cystatin C [mg/mL] | 0, 4, 24h post-dose |
| Glomerular filtration rate [mL/min] | 0, 4, 24h post-dose |
| Serum glucose [mg/dL] | 0, 24h post-dose |